activation of β-catenin signaling, and treatment of cancer comprises determining if the tumor or cancer comprises a RSPO gene fusion.

22. The antibody for use according to any one of claims 15-17 or the use according to claim 18 or claim 19, wherein the tumor or the cancer has an elevated expression or a high expression level of RSPO3.

23. The antibody for use according to any one of claims 15-17 or the use according to claim 18 or claim 19, wherein the inhibiting tumor growth, inducing differentiation of tumor cells, inhibiting β-catenin signaling in a cell, treatment of a disease associated with activation of β-catenin signaling, and treatment of cancer comprises determining if the tumor or cancer has an elevated expression or a high expression level of RSPO3.

24. The antibody for use according to any one of claims 15-17 and 20-23 or the use according to claim 18 or claim 19, wherein the antibody is to be administered with at least one additional therapeutic agent.

25. The antibody for use according to or the use of claim 24, wherein the at least one additional therapeutic agent is a chemotherapeutic agent, an angiogenesis inhibitor, or an additional antibody.

26. An *in vitro* method of identifying a tumor for treatment with an antibody according to any one of claims 1-8 comprising: determining if the tumor that has an elevated expression or a high expression level of RSPO3.

27. The method according to claim 26, wherein the expression level of RSPO3 is determined by a PCR-based assay, microarray analysis, or nucleotide sequencing.